Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASiC-CIC: Colchicine for Prevention of Chemotherapy-Induced Cardiomyopathy
NCT06304896Phase 1Not yet recruiting
- Sponsor
- Arab Contractors Medical Centre
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of colchicine in chemotherapy-induced cardiomyopathy (CICM) (3 arms), sponsored by Arab Contractors Medical Centre. Primary endpoint: Chemotherapy-induced cardiomyopathy at 6 months. Planned start May 2024; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
chemotherapy-induced cardiomyopathy (CICM)
Beyond the preview
Go deeper on NCT06304896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304896.